期刊文献+

多巴胺受体激动剂戒断综合征 被引量:5

下载PDF
导出
摘要 多巴胺受体激动剂戒断综合征(dopamine agonist withdrawal svndrome,DAWS)是指与多巴胺受体激动剂减量剂量依赖性相关的,可导致有临床意义的困扰或者社会/职业功能障碍。DAWS是不能被除多巴胺激动剂减量或停用以外的其他临床因素所导致的,严重的、刻板的神经精神症候群,难以用左旋多巴和其他抗帕金森病药物治疗缓解。DAWS患者生活质量以及社会功能严重下降,可有自杀行为,应引起临床医师高度重视。
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2013年第1期53-53,61,62,共3页 Chinese Journal of Nervous and Mental Diseases
  • 相关文献

参考文献13

  • 1Evans AH,Lawrence AD,Cresswell SA. Compulsive use of dopaminergie drug therapy in Parkinson' s disease:reward and anti-reward[J].Movement Disorders,2010,(07):867-876.
  • 2Dorfman B J,Nirenberg MJ. Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome[J].Parkinsonism and Related Disorders,2012.
  • 3Rabinak CA,Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease[J].Archives of Neurology,2010,(01):58-63.
  • 4Cunnington AL,White L,Hood K. llentification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease[J].Parkinsonism and Related Disorders,2012,(09):1051-1052.
  • 5张少平,周天骍,张明园,王纪明,江渝琦.社区神经症的临床特征与亚型分类探讨[J].中国神经精神疾病杂志,2001,27(3):206-208. 被引量:6
  • 6许秀峰.神经症性障碍[A]北京:人民卫生出版社,2008113-130.
  • 7Lim SY,Evans AH,Miyasaki JM. Impulse control and related disorders in Parkinson' s disease:review[J].Annals of the New York Academy of Sciences,2008.85-107.
  • 8Schlesinger I,Erikh I,Zaaroor M. Dopamine agonist withdrawal syndrome:the apomorphine solution[J].Archives of Neurology,2010,(09):1155.
  • 9Stephane T,Emmanuel B,Magaly AK. Reply:Dopamine agonist withdrawal syndrome and non-motor symptoms after Parkinson ' s disease surgery[J].Brain,2010.1-4.
  • 10Melissa JN,Christina AR. Dopamine Agonist Withdrawal Syndrome:The Apomorphine Solution--Reply[J].Archives of Neurology,2010,(09):1156.

二级参考文献11

  • 1陶明毅,王希达,施慎逊.抑郁性神经症与抑郁症的诊断范畴问题[J].上海精神医学,1994,6(3):138-141. 被引量:9
  • 2张少平,王纪明.地段医院中神经症的8年随访诊断分析[J].中华神经精神科杂志,1994,27(2):105-107. 被引量:3
  • 3Toru M, Matsuda O, Makiguch K, et al. Neuroleptic malignant syndrome like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis, 1981,169:324-327.
  • 4Friedman JH, Feinberg SS, Feldman RG. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA, 1985,15: 2792-2795.
  • 5Gihh WR, Griffith DN. Levodopa withdrawal syndrome identical to neuroleptic malignant Syndrome. Postgrad Med J,1986,62:59-60.
  • 6Rascol O, Salachas F, Montastruc JL. Neuroleptic malignantlike syndrome following levodopa withdrawal. Rev Neurol,1990,146:215-218.
  • 7Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatr, 1987,22 : 1004-102.
  • 8Horn E, Lach B, Lapierre Y, et al. Hypothalamic pathology in the neuroleptic malignant syndrome. Am J Psychiatr, 1988:145:617-620.
  • 9MizunoY, Takubo H, Mizuta E, et al. Concept and review of malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord, 2003,9 :S3-S9.
  • 10Kornhuber J, Weller M. Neuroleptic malignant syndrome. Curr Opin Neurol, 1994,7 : 353-357.

共引文献10

同被引文献74

  • 1余守雅,杜英汉.肝风1例治验[J].北京中医药大学学报(中医临床版),2004,11(3):39-40. 被引量:1
  • 2胡剑秋,吴云华,范宏涛,熊辅信.熊辅信主任治疗震颤性麻痹的思路[J].云南中医中药杂志,2005,26(1):4-5. 被引量:1
  • 3周义先,鲍远程.中西医结合治疗帕金森病30例[J].现代中西医结合杂志,2006,15(12):1642-1642. 被引量:3
  • 4王健,韩臣柏.病理性购物[J].临床精神医学杂志,2007,17(3):207-208. 被引量:1
  • 5刘毅,王慧新,李如奎.止颤汤治疗帕金森病的临床疗效观察[J].中西医结合心脑血管病杂志,2007,5(11):1064-1065. 被引量:20
  • 6Claassen DO,van den Wildenberg WP,Ridderinkhof KR,et al.The risky business of dopamine agonists in Parkinson disease and impulse control disorders[J] .Behav Neurosci,2011,125(4):492-500.
  • 7Herrero MT,Pagonabarraga J,Linazasoro G.Neuroprotective role of dopamine agonists:evidence from animal models and clinical studies[J] .Neurologist,2011,17(6 Suppl 1):S54-S66.
  • 8Rasmussen VG,Poulsen SH,Dupont E,et al.Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists:a treatment-blinded echocardiographic study[J] .J Heart Valve Dis.2009,18(4):463-469.
  • 9Gogoi S,Antonio T,Rajagopalan S,et al.Dopamine D(2)/D(3) agonists with potent iron chelation,antioxidant and neuroprotective properties:potential implication in symptomatic and neuroprotective treatment of Parkinson's disease[J] .ChemMedChem.2011,6(6):991-995.
  • 10Wylie SA,Claassen DO,Huizenga HM,et al.Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease[J] .J Cogn Neurosci,2012,24(8):1709-1724.

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部